Z-WEHD-FMK
(Synonyms: N-[苄氧羰基]-L-色氨酰-L-ALPHA-谷氨酰-N-[(1S)-3-氟-1-(2-甲氧基-2-氧代乙基)-2-氧代丙基]-L-组胺酰胺甲基酯,Z-WEHD-FMK, Caspase-5 Inhibitor (fluoromethylketone)) 目录号 : GC12190
Z-WEHD-FMK 是一种有效的、细胞渗透性和不可逆的 caspase-1/5 抑制剂。 Z-WEHD-FMK 还表现出对组织蛋白酶 B 活性的强大抑制作用 (IC50=6 μM)。 Z-WEHD-FMK 可用于研究细胞凋亡的证据。
Cas No.:210345-00-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. Golgin-84 cleavage was blocked via treatment of infected cells with Z-WEHD-FMK, resulting in a lack of Golgi fragmentation and a 2-log reduction in numbers of infectious bacteria.
We treated infected cells with Z-WEHD-FMK, effectively preventing Golgi fragmentation, or with DMSO as a control and then labelled cells with fluorescent ceramide. Confocal images revealed that ceramide was rapidly incorporated into the inclusion membrane within DMSO-treated cells and accumulated inside the inclusion in bacterial membranes. In contrast, Z-WEHD-FMK-treated cells were only slightly fluorescent as the majority of lipid accumulated in a Golgi-like structure outside the inclusion1.
General caspase inhibitor (Z-Asp-CHz-DCB) and capase-5 inhibitor (Z-WEHD-FMK) could not induce rRNA fragmentation treated with ECyd. Caspase-5 (ICErei Ill/TY), member of ICE protease, activated pathway may be concerned with ECyd induced rRNA fragmentation2.
References:
1. D. Heuer, A.R. Lipinski et al. Chlamydia causes fragmentation of the Golgi compartment to ensure reproduction. NATURE, 457, 2009
2. Kamada, S., Funahashi, Y. and Tsujimoto, Y.(1997) Cell Death Diff. 4, 473-478.
| Cas No. | 210345-00-9 | SDF | |
| 别名 | N-[苄氧羰基]-L-色氨酰-L-ALPHA-谷氨酰-N-[(1S)-3-氟-1-(2-甲氧基-2-氧代乙基)-2-氧代丙基]-L-组胺酰胺甲基酯,Z-WEHD-FMK, Caspase-5 Inhibitor (fluoromethylketone) | ||
| 化学名 | methyl (4S)-5-[[(2S)-1-[[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-3-(1H-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-5-oxopentanoate | ||
| Canonical SMILES | COC(=O)CCC(C(=O)NC(CC1=CN=CN1)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4 | ||
| 分子式 | C37H42FN7O11 | 分子量 | 763.78 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3093 mL | 6.5464 mL | 13.0928 mL |
| 5 mM | 0.2619 mL | 1.3093 mL | 2.6186 mL |
| 10 mM | 0.1309 mL | 0.6546 mL | 1.3093 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet